FindTrial
Sign In

Canceled by the investigator. Study on the regulatory mechanism of dexmedetomidine on pulmonary AQP1 and AQP5 in patients with one-lung ventilation

Study on the regulatory mechanism of dexmedetomidine on pulmonary AQP1 and AQP5 in patients with one-lung ventilation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069724
Enrollment
Unknown
Registered
2023-03-24
Start date
2023-03-24
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung injury

Interventions

D1 group:Low dose dexmedetomidine
D2 group:High dose dexmedetomidine
control group:blank control

Sponsors

Nanxishan Hospital of Guangxi Zhuang Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients who underwent radical lung cancer surgery and OLV was more than 2 h.

Exclusion criteria

Exclusion criteria: preoperative history of tumor radiotherapy or chemotherapy exposure, immune or endocrine system diseases, hepatic or renal dysfunction, preoperative corticosteroid use, a recent history of respiratory infection or chronic lung disease, preoperative sick sinus syndrome or atrioventricular block.

Design outcomes

Primary

MeasureTime frame
TNF-a;IL-8;AQP1;AQP5;—

Secondary

MeasureTime frame
Blood gas analysis;Hemodynamic changes;Single lung ventilation time;Operation time;Total blood loss;Total infusion volume;—

Countries

China

Contacts

Public ContactLi Yuanqiang

Nanxishan Hospital of Guangxi Zhuang Autonomous Region

67443434@qq.com15078348351

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026